



*Advancing Life Sciences Together*

As a company specializing in the supply of pharmaceutical filtration goods and services, Millipore has been actively involved in the AstraZeneca Australia operation for over 30 years. In that time, Millipore Corporation has grown into a globally respected Life Science organization earning annual revenues worth over USD1.3bn with more than 6000 employees in 47 countries worldwide.

In 1999 the rapid expansion of the AstraZeneca manufacturing site precipitated a management decision to review the company's overall requirements for process filtration and QA monitoring tools. Millipore succeeded in winning the tender to become AstraZeneca's preferred supplier by demonstrating its unique focus and unparalleled depth of experience in the field of Biopharmaceutical purification.

The process of partnering began immediately. Millipore's front-line representatives are fully qualified engineers and scientists enhancing the company's overall technical capability. Millipore quickly developed strong working relationships throughout the organization with key stakeholders in Procurement, Engineering, Production, Validation and QA.

To this day, the Millipore account managers are on call to the site at all times and visits occur on a weekly basis for technical discussions and inventory review. A half-year review report is issued by Millipore, summarizing agreed KPIs, inventory review, activities and upcoming events.

Since 1999, in the face of increasingly stringent regulatory requirements, Millipore has worked with AstraZeneca Australia to achieve the following significant milestones:

- Achieving manufacturing compliance to PIC/S (European) GMP.
- Validated filtration for 8 sterile BFS filling lines, including hundreds of hours of process simulations in US laboratories.
- Development of Standard Operating Procedures and formal operator training programmes.
- Continuous lowering of cost.

Millipore's active participation in AstraZeneca's operations means that it is ideally placed to respond immediately to changing priorities and future needs. Millipore's main KPI is to continuously decrease the cost of filters per filled ampoule for AstraZeneca. In this we have been successful since 1999.

Millipore looks forward to another 30 years of excellence in supply partnering with AstraZeneca Australia.